PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 11, 2014, Pages 8295-8303

  Wen, Feifei ^a   He, Shuang ^a   Sun, Chenbo ^a   Li, Tangyue ^a   Wu, Shuhua ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Mdr; Pik3ca; Pik3cb; Prognosis

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PIK3CB PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DISEASE COURSE; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; ADULT; AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84919667404     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Szakacs G, paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
3. Rodriguez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006; 12: 4411-4425.
4. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL-2 in human gastric cancer cell. Int J Cancer 2008; 123: 372-79.
5. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
6. Zhang J, Roberts TM, Shivdasani RA Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 2011; 141: 50-61.
7. Binbin Cui, Ji Tao, Yanmei Y. Studies on the Expression Patterns of Class I PI3K Catalytic Subunits and Its Prognostic Significance in Colorectal Cancer. Cell Biochem Biophys 2012; 62: 47-54.
8. Zhu YF, Yu BH, Li DL, Ke HL, Guo XZ, Xiao XY. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol 2012; 18: 3745-3751.
9. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Review Drug Discovery 2009; 8: 627-644.
10. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-19.
11. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18: 77-82.
12. Crowell JA, Steele VE and Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007; 6: 2139-2148.
13. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vo-gelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
14. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM and Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 2008; 415: 97-110.
15. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM and Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008; 105: 13057-13062.
16. Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A, Grotzer MA, Arcaro A. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008; 14: 1172-1181.
17. Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 2014; 6: 154-66.
18. Park MS, Dong SM, Kim BR, Seo SH, Kang S, Lee EJ, Lee SH, Rho SB. Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts. Oncotarget 2014; 5: 4929-34.
19. Yuen JW, Chung GT, Lun SW, Cheung CC, To KF, Lo KW. Epigenetic Inactivation of Inositol polyphosphate 4-phosphatase B (INPP4B), a Regulator of PI3K/AKT Signaling Pathway in EBV-Associated Nasopharyngeal Carcinoma. PLoS One 2014; 9: e105163.
20. Zhu LB, Jiang J, Zhu XP, Wang TF, Chen XY, Luo QF, Shu Y, Liu ZL, Huang SH. Knockdown of Au-rora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-?B signaling pathway. Int J Clin Exp Pathol 2014; 7: 3984-91.
21. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL-2 in human gastric cancer cell. Int J Cancer 2008; 123: 372-9.
22. Xie X, Tang B, Zhou J, Gao Q, Zhang P. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep 2013; 30: 773-82.
23. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, Wu K, Fan D. Hypoxia-inducible factor-1a contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008; 99: 121-8.
24. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O, Arcaro A. Targeting the PI3K p110 Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration. Clin Cancer Res 2008; 14: 6761-6769.
25. Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ. Targeted inhibition of phosphatidyl inositol-3-kinase p110b, but not p110a, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis 2013; 18: 509-20.
26. El-Readi MZ, Hamdan D, Farrag N, El-Shazly A, Wink M. Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur J Pharmacol 2010; 626: 139-145.
27. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB and Unate H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-?B signaling. Oncogene 2002; 21: 1945-1954.
28. Barancík M, Bohácová V, Sedlák J, Sulová Z and Breier A. LY294, 002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes Pglycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2006; 29: 426-434.
29. García MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kB in murine lymphoma cell lines. Leuk Res 2009; 33: 288-96.
30. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
31. Nuutinen U, Postila V, Mättö M, Eeva J, Rop-ponen A, Eray M, Riikonen P and Pelkonen J.Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line. Exp Cell Res 2006 312: 322-330.
32. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003; 63: 2172-2178.